The effects of diet and orlistat on body weight and lipid profiles in high risk Chinese patients with coronary artery disease, obesity and hypercholesterolemia

Irish Journal of Medical Science

Volumn 178, Issue 2, 2009, Pages 173-178

  Chan, K W ^a   Leung, W S ^a   Fung, Y S ^a   Hung, H F ^a   Tsui, P ^a   Chu, H ^a   Chan, Y W ^a   Ko, G T C ^b   Yeung, V T F ^c  

^a PRINCESS MARGARET HOSPITAL   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Our Lady of Maryknoll Hospital Hong Kong   (Hong Kong)

Author keywords

Coronary artery disease; Hypercholesterolemia; Obesity; Orlistat

Indexed keywords

GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; ANTIOBESITY AGENT; LACTONE; LIPID;

ABDOMINAL PAIN; ABNORMAL FECES; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; BODY WEIGHT; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DEFECATION DISORDER; DEFECATION URGENCY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; FECES INCONTINENCE; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MALE; NAUSEA; OBESITY; SPOTTING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; ANALYSIS OF VARIANCE; BLOOD; DIET; DRUG EFFECTS; HONG KONG; MIDDLE AGED; MOTOR ACTIVITY; NUTRITIONAL STATUS; PROSPECTIVE STUDY; RISK ASSESSMENT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-OBESITY AGENTS; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DIET; FEMALE; HONG KONG; HUMANS; HYPERCHOLESTEROLEMIA; LACTONES; LIPIDS; MALE; MIDDLE AGED; MOTOR ACTIVITY; NUTRITIONAL STATUS; OBESITY; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 67649520256     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11845-009-0291-y     Document Type: Article

References (20)

1. Woo KS, Donnan SPB (1989) Epidemiology of coronary arterial disease in the Chinese. Intern J Card 24:83-93. doi: 10.1016/0167-5273(89)90045-4
2. Department of Health, Government of the Hong Kong Special Administrative Region (2004). Department of Health Annual Report 2003/2004:34
3. Janus ED, Postiglione A, Singh RB, Lewis B (1996) The modernization of Asia: Implications for coronary heart disease. Circulation 94:2671-2673
4. Montaye M, De Bacquer D, De Backer G, Amouyel P (2000) Overweight and obesity: A major challenge for coronary heart disease secondary prevention in clinical practice in Europe. Eur Heart J 21:808-813. doi: 10.1053/euhj.1999.1854
5. Zavoral JH (1998) Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 16:2013-2017. doi: 10.1097/ 00004872-199816121-00024
6. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D et al (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomised controlled trial. JAMA 281:235-242. doi: 10.1001/jama.281.3.235
7. Altman DG (1982) How large a sample? In: Gore SM, Altman DG (eds) Statistics in practice. British Medical Association, London, pp 6-8
8. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (1993) Summary of the second report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 269:3015-3023
9. Smith SC, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K et al (2001) AHA/ACC guidelines for preventing heart attack and death in patientA with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 104:1577-1579. doi: 10.1161/hc3801.097475
10. Thomas DR, Heckbert SR, Kaplan RC, Psaty BM, Smith NL, Lemaitre RN et al (2001) Body mass index and the risk of recurrent coronary events following acute myocardial infarction. Am J Cardiol 88:467-472. doi: 10.1016/S0002-9149(01)01720-9
11. Hoit BD, Gilpin EA, Maisel AA, Henning H, Carlisle J, Ross J Jr (1987) Influence of obesity on morbidity and mortality after acute myocardial infarction. Am Heart J 114:1334-1341. doi: 10.1016/0002-8703(87)90534-5
12. Eckel RH, Krauss RM (1998) American Heart Association call to action: obesity as a major risk factor for coronary heart disease. Circulation 97:2099-2100
13. Van Gaal LF, Broom JI, Enzi G, Toplak H (1998) Efficacy and tolerability of orlistat in the treatment of obesity: A 6-month dose-ranging study. Eur J Clin Pharmacol 54:125-132. doi: 10.1007/s002280050433
14. Sjöström Lars, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP et al (1998) Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352:167-172. doi: 10.1016/S0140-6736(97)11509-4
15. Hutton B, Fergusson D (2004) Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: A systemic review of randomized clinical trials. Am J Clin Nutr 80:1461-1468
16. World Health Organisation Western Pacific Region, International Association for the Study of Obesity, International Obesity Task Force (2000) The Asia-Pacific perspective: Redefining obesity and its treatment. February 2000:35
17. Dattilo AM, Kris-Etherton PM (1992) Effects of weight reduction on blood lipids and lipoproteins: A meta-analysis. Am J Clin Nutr 56:320-328
18. Muls E, Kolanowski J, Scheen A, Van Gaal L (2001) The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: A randomised, double-blind, placebo-controlled, multicenter study. Int J Obes Relat Metab Disord 25:1713-1721. doi: 10.1038/sj.ijo.0801814
19. Tong PC, Lee ZS, Sea MM, Chow CC, Ko GT, Chan WB et al (2002) The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med 162:2428-2435. doi: 10.1001/archinte.162.21.2428
20. Expert panel on detection, evaluation, treatment of high blood cholesterol in adults (2001) Executive summary of the third report of the national cholesterol education program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 285:2486-2497